Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ProQR Therapeutics N.V (PRQR) Long-Term Investments: 2021-2023

Historic Long-Term Investments for ProQR Therapeutics N.V (PRQR) over the last 2 years, with Jun 2023 value amounting to $676,222.

  • ProQR Therapeutics N.V's Long-Term Investments rose 2.05% to $676,222 in Q2 2023 from the same period last year, while for Jun 2023 it was $676,222, marking a year-over-year increase of 2.05%. This contributed to the annual value of $633,574 for FY2022, which is 6592.32% up from last year.
  • Latest data reveals that ProQR Therapeutics N.V reported Long-Term Investments of $676,222 as of Q2 2023, which was up 1.45% from $666,545 recorded in Q1 2023.
  • In the past 5 years, ProQR Therapeutics N.V's Long-Term Investments registered a high of $747,853 during Q2 2021, and its lowest value of $749.07 during Q1 2021.
  • For the 3-year period, ProQR Therapeutics N.V's Long-Term Investments averaged around $545,218, with its median value being $664,594 (2023).
  • The largest annual percentage gain for ProQR Therapeutics N.V's Long-Term Investments in the last 5 years was 92,944.61% (2022), contrasted with its biggest fall of 14.50% (2022).
  • Over the past 3 years, ProQR Therapeutics N.V's Long-Term Investments (Quarterly) stood at $9,152 in 2021, then spiked by 6,822.96% to $633,574 in 2022, then climbed by 2.05% to $676,222 in 2023.
  • Its Long-Term Investments stands at $676,222 for Q2 2023, versus $666,545 for Q1 2023 and $633,574 for Q4 2022.